TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥ 18 years of old.~2. Clinical diagnosis of type 1 diabetes for at least one year.~3. HbA1c ≤ 9.5%.~4. Patients using multiple daily injections with basal-bolus insulin regimen and insulin analogs (pre-meal: Aspart, Lispro, Guilisine or Fiasp; basal: Detemir, Glargine U100 \& U300, Degludec U100).~5. Written informed consent given.~Exclusion Criteria:~1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.~2. Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.~3. Anemia (Hb \< 100g/L).~4. Ongoing pregnancy or breastfeeding.~5. Severe hypoglycemic episode within two weeks of screening.~6. Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).~7. Ongoing treatment with CSII (Continuous Subcutaneous Insulin Infusion) insulin pump therapy.~8. Participation to a clinical trial in the last 3 months prior to inclusion in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspart - 60-minutes postprandial exercise (Type: ACTIVE_COMPARATOR): None
- Aspart - 120-minutes postprandial exercise (Type: ACTIVE_COMPARATOR): None
- FiAsp - 60-minutes postprandial exercise (Type: ACTIVE_COMPARATOR): None
- FiAsp - 120-minutes postprandial exercise (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* euthyroid adults (normal TSH)~* no criteria for malignancy is present (size, fine needle aspiration, lymph nodules)~* no other medication/supplement administered for thyroid, no steroids, beta-blocker~Exclusion Criteria:~* suspicion of malignancy / shown~* autoimmune disease~* abnormal thyroid function~* Wilson disease~* contraception with intrauterine device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preparation with Spirulina (Type: ACTIVE_COMPARATOR): 6 weeks bid Preparation with Spirulina
- Placebo (Type: PLACEBO_COMPARATOR): 6 weeks bid Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Medical history and symptoms of knee osteoarthritis~Exclusion Criteria:~* Any other disease or medication affecting the bone or cartilage.~* Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial.

- Gender: ALL
- Minimum Age: 52 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant people, ages 18 years or older~* Intrauterine pregnancy between 18/0-28/0 weeks of gestation age (by ultrasound dating performed prior to or same day of enrollment visit)~* Consented for an induced, elective abortion or undergoing induction for demise~* English or Spanish speaking~* Able to consent for a research study, literate in English or Spanish~* Willing to comply with study procedures and follow-up~* Access to smart phone throughout study~Exclusion Criteria:~* Prior mastectomy (breast reduction or chest masculinization surgery acceptable)~* Currently breastfeeding~* Currently receiving dopamine agonist therapy for other indication (prolactinoma, Cushings syndrome, acromegaly, restless leg syndrome)~* Contraindication to cabergoline (as per package insert)~  * Uncontrolled hypertension - defined as baseline BP \> 150/100, or chronic hypertension requiring more than one baseline medication, or pregnancy-induced hypertension spectrum disorders (gestational hypertension, preeclampsia, eclampsia)~ * History of cardiac valvular disorders or valvular repair~ * History of pulmonary, pericardial, or retroperitoneal fibrotic disorders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabergoline (Type: EXPERIMENTAL): After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
- Placebo (Type: PLACEBO_COMPARATOR): After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with heterozygous familial hypercholesterolemia who were not adequately controlled with their lipid-modifying therapy~Exclusion criteria:~* Age \< 18 years or legal age of adulthood, whichever is greater~* LDL-C \< 70 mg/dL (1.81 mmol/L) and with cardiovascular disease~* LDL-C \< 100 mg/dL (2.59 mmol/L) and without cardiovascular disease~* Fasting serum triglycerides \> 400 mg/dL (4.52 mmol/L)~* Known history of homozygous familial hypercholesterolemia~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
- Alirocumab 75 mg/Up to 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* admission to the intensive care unit (ICU) or to the post-operative cardiosurgical ICU (PC-ICU)~* ICU/PC-ICU stay for at least 1 night~Exclusion Criteria:~* known allergy to chlorhexidine~* burns, toxic epidermal necrolysis or Stevens-Johnson syndrome as admission diagnosis~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
- Control Arm (Type: ACTIVE_COMPARATOR): daily bathing with standard soap

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A. Older than 19 years old and younger than 80 years old B. Pathologically confirmed gastric adenoma and/or early gastric cancer C. Iatrogenic gastric ulcer after ESD(Endoscopic submucosal dissection) more than 40mm (at prediction) D. Patients who is taking medication such at aspirin and/or coumadin (and other anti-coagulation medication) E. ECOG performance status 0 or 1 F. Adequate renal function (serum creatinine \< 1.5 mg/dL or calculated creatinine clearance ≥ 60 ml/min) G. Adequate liver function (total bilirubin \< 1.5 X the upper limits of normal (ULN), AST and ALT \<3 X UNL, and alkaline phosphatases \< 3 X ULN or \< 5 x ULN in case of liver involvement) H. Adequate BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) I. Subjects who given written informed consent after being given a full description of the study~Exclusion Criteria:~A. Previously treated by radical gastrectomy B. Adverse effect on this medication C. Pregnant or on breast feeding D. Patients who are unwilling or unable to provide informed consent, such as those with psychiatric problem, drug abuse or alcoholism

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Endo-Clot(TM) (Type: EXPERIMENTAL): The intervention group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Active Limb Orthosis for Home-Use Stroke Hemiparetic Gait Rehabilitation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 21-80~* one or more cerebral strokes, but all strokes on same side~* a stroke at least 6 months prior to enrollment~* Gait asymmetry, but able to walk independently with or without a cane~* Not currently receiving physical therapy~* no evidence of severe cognitive impairment that would interfere with understanding the instructions~* no evidence of one-sided neglect, affecting ambulation~* At least 25 feet of walking space in home (does not need to be a straight line)~* Weight does not exceed 250 lbs~Exclusion Criteria:~* uncontrolled seizures~* metal implants (stents, clips, pacemaker)~* pregnancy~* History of a neurological disorder other than stroke ( Parkinson's, MS)~* Chronic Obstructive Pulmonary Disease~* Uncontrolled blood pressure~* Head injury in the past 90 days~* A myocardial infarction within the last 180 days~* Cannot rely on a rolling walker for ambulation

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- wearing the iStride device (Type: EXPERIMENTAL): The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Actual or planned therapy with tigecycline.~* At least 18 years old.~Exclusion Criteria:~* Hypersensitivity to antibiotics or tigecycline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males or females between the ages of 18 and 70 years~* Body mass index (BMI) between 18 and 32 kg/m\^2, inclusive~* Females could not be pregnant or breast feeding and had to be using birth control~Exclusion Criteria:~* Positive drug screen for substances of abuse~* Positive results for HIV, hepatitis B, or hepatitis C~* Screening 12-lead ECG demonstrating QTc interval \>430 msec for males and \>450 msec for females, or any cardiac rhythm disorder considered by the Investigator to be clinically relevant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- CLP 15 g Fed (Type: EXPERIMENTAL): Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
- CLP 25 g Fed (Type: EXPERIMENTAL): Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
- CLP 7.5 g Fed (Type: EXPERIMENTAL): Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
- CLP 15 g fasted (Type: EXPERIMENTAL): Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female at least 18 years of age~* Must have gastric cancer or gastroesophageal junction cancer that cannot be operated on and that is advanced or has spread out~* Did not receive neoadjuvant or adjuvant treatment (chemotherapy, radiotherapy, or both) for their disease within the last 6 months~* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work~* Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study~Exclusion Criteria:~* Presence of tumor cells in the brain or spinal cord that have not been treated~* Active known or suspected autoimmune disease~* Any serious or uncontrolled medical disorder or active infection~* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)~* Any positive test result for hepatitis B or C indicating acute or chronic infection~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm
- XELOX (Oxaliplatin + Capecitabine) (Type: ACTIVE_COMPARATOR): None
- FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil) (Type: ACTIVE_COMPARATOR): None
- Nivolumab + XELOX (Type: EXPERIMENTAL): None
- Nivolumab + FOLFOX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females with Chronic Hepatitis C (HCV) Genotype 1,4,5,6, or indeterminate~* Naive to previous HCV treatment~Exclusion Criteria:~* Positive for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab~* History of any other clinically significant chronic liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+PEG+RBV 12 weeks (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
- SOF+PEG+RBV 24 weeks (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
- SOF+PEG+RBV 12 week/Rerandomization Group (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~The participants have to meet all of the following criteria to be eligible to enter the study:~* Willing and able to provide informed consent~* Male or female and aged 18 years or above~* Volunteers able to read and understand English~* A personal history of atopic dermatitis~Exclusion Criteria:~Participants meeting any of the following criteria will not be permitted to enter the study:~* Eczema on the volar forearms requiring anti-inflammatory treatment~* Possible allergy to ingredients in the study medications.~* Any serious current medical condition which, in the opinion of the Investigator, may interfere with the evaluation of the results or may be contraindicated by the use of the test medications~* Use of any concomitant medication that may interfere with the study related activities or assessment of efficacy, as judged by the Investigator~* Use of any topical product, including cosmetic leave-on products on the volar forearms, within 1 week prior to, and throughout the study~* Female participant who, according to the participant, is pregnant or breast-feeding, or plans to become pregnant during the course of the study~* Any participant-related factor suggesting potential poor compliance with study procedures (e.g. psychiatric disorders, history of alcohol or substance abuse), as judged by the Investigator~* Enrolment in any interventional study or use of an investigational drug within 3 months prior to the screening visit~* Volunteers judged by the PI to be inappropriate for the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test cream (2% urea/20% glycerol) (Type: EXPERIMENTAL): Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
- Reference cream 1: Miniderm® 20% cream (20% glycerol) (Type: ACTIVE_COMPARATOR): Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
- Reference cream 2: Diprobase® cream (cream without humectants) (Type: ACTIVE_COMPARATOR): Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
- Untreated (Type: NO_INTERVENTION): Untreated skin area on the volar forearm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete